Press review

 - 

Pharma manager to run the German e-health card consortium

Country : China, France, Germany, U.S.

Keywords :
BERLIN 21 June (APM) - Health Minister Jens Spahn has appointed Markus Leyck Dieken, head of Shionogi Germany, to lead the German e-health card consortium Gematik, Frankfurter Allgemeine Zeitung (FAZ) reported on Monday (p20).
Leyck Dieken will be designated on 21 June at Gematik's shareholder meeting in which the Health Ministry has a majority stake and will take office on 1 July (APMHE 63399).
Spahn intends to use Gematik as a key body in its digital health strategy in order to accelerate the deployment of electronic health cards and electronic health records.

Sanofi cuts 144 jobs in Frankfurt

Sanofi plans to cut 144 jobs in diabetes research at its largest plant in Frankfurt-Höchst as it is restructuring its research and development capacities, FAZ says on Friday (p21) (APMHE 63404).
Sanofi, which manages its diabetes business from Höchst, "is steaming down diabetes research", works council chairman Michael Klippel told FAZ.
Currently, around 3,000 jobs in Höchst are connected to the diabetes medicine business.

China's Fosun considers buying Bayer's animal health business

Chinese conglomerate Fosun international is considering bidding in a joint deal with a private equity firm for Bayer's animal-health business, said Handelsblatt (p27) and FAZ FAZ (p21) on Tuesday (APMHE 63357).
The deal could be worth €6 to €8 billion. The sales process is expected to begin in the coming weeks and is not expected to be finalized until the beginning of 2020.

Versum shareholders agree to Merck KGaA deal

Merck KGaA was able to convince shareholders of U.S. electronic materials maker Versum Materials to agree to a $53 per share takeover, FAZ said on Wednesday (p20).
After some reluctance by Versum's management and Merck increasing its offer, Merck signed a definitive agreement to buy Versum for $6.5 billion in April (APMHE 62667). The acquisition is expected to be completed in the second half of 2019.

Payer group criticises costs of new health laws in Germany

The quick succession of cost-intensive new health laws in Germany is a challenge to statutory health insurance's €21 billion financial reserves, chair of umbrella payer group GKV-Spitzenverband Doris Pfeiffer told FAZ on Tuesday (p19).
For instance, statutory payers will have to pay for an increase of psychotherapists' remunerations, high digitisation costs, the reimbursement of medical apps (APMHE 63010) or developing electronic health records for their insurees.
Statutory payers' financial situation is stable despite increasing costs of 4% per insuree in the first quarter, compared to increasing revenues of 3% per insuree.

Six hundred names on Monsanto's lobbying listing

German group Bayer said on Twitter that 600 names have been collected since 2015 in France and Germany by public relations agencies for weed-killer maker Monsanto, mapping advocates and opponents for glyphosate and gene technology, SZ reported on Tuesday (p17).
Bayer learned about these lists after it acquired Monsanto in June 2018, and the group has commissioned law firm Sidley Austin to write letters to all the people on the lists. Such lists also exist for five other European countries, Bayer has acknowledged.

Sanofi and Google deepening collaboration

Sanofi and Google have deepened their collaboration by building a joint innovation lab combining Sanofi's R&D data repository with Google's data analytics in the virtual space, FAZ reported on Wednesday (p22) (APMHE 63365).
In 2016, the companies started diabetes joint venture Onduo (APMHE 49497). The aim is to reduce R&D time and deliver "even more personalised data" for new therapies but also optimise marketing and predict sales more precisely, using Google's artificial intelligence, FAZ wrote.

Pfizer buys Array to keep pace in oncology

Pfizer will buy cancer biotech Array Biopharma for $11 billion to keep pace in the oncology business, wrote Handelsblatt on Tuesday (p23).
The move comes after several deals from big pharma companies in oncology, especially the $88 billion acquisition of Celgene by Bristol-Myers Squibb (BMS).
Pfizer's oncology business lags significantly behind the leaders Roche, Novartis and BMS while Merck & Co, Astra-Zeneca and Johnson & Johnson have recently posted stronger growth in this area.

Low trust in vaccination in Western Europe

Trust in vaccination is low in Western Europe, according to a global survey of public attitudes toward science and health by the British Wellcome Trust Foundation, said Die Welt on Thursday (p20).
Worldwide 79% of people believe vaccines are safe but only 59% in Western Europe do, according to the "Wellcome Global Monitor 2018" included 140,000 people.
While trust is the highest in Bangladesh and Rwanda (97% and 94%), French people are the most suspicious.
hm/so/nm

[HM5PT8FXQ]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.